Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
By addressing insulin resistance more effectively than any previous pharmaceutical option, and producing weight loss that was previously achievable only through surgery, these medications treat the root cause
We recognize that everyones weight loss journey is unique
In phase III: Semaglutide 2.4 mg (STEP-1): nausea 44.2%, diarrhea 31.5%, vomiting 24.8% Tirzepatide 15 mg (SURMOUNT-1): nausea 29.2%, diarrhea 23.0%, constipation 16.8% Retatrutide 12 mg (TRIUMPH-1): nausea 37.2%, vomiting 22.0%, diarrhea 27.1% Key observation: tirzepatide shows the most favorable GI profile at equivalent dose, likely tied to the GIP component dampening GLP-1-mediated nausea signaling at the brainstem level
Some researchers lose more
With tirzepatide specifically, microdosing means different things to different people
US$ 22.67
US$ 24.57
US$ 27.41
